Metrics to compare | ENVB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipENVBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −2.4x | −0.5x | |
PEG Ratio | −0.01 | −0.03 | 0.00 | |
Price/Book | 1.6x | 2.6x | 2.6x | |
Price / LTM Sales | - | 3.1x | 3.1x | |
Upside (Analyst Target) | - | 104.8% | 53.2% | |
Fair Value Upside | Unlock | 5.1% | 6.2% | Unlock |
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.